GeNeuro is a Swiss biotechnology company focused on research and development of therapies targeting human endogenous retrovirus proteins in neurological and autoimmune diseases. The company has been listed in liquidation proceedings.
No data available
Are you interested in the impact of this company or this ETF?
It seems we haven't collected any data here yet. Just let us know and we will try to find data as soon as possible. Thank you for your feedback!